Divi's Labs Q2 results: net profit rises 63.6% to Rs 1,127 crore
Divi's Laboratories told the National Stock Exchange its consolidated Q2 FY27 net profit rose 63.6% to Rs 1,127 crore, and revenue from operations rose 35.4% to Rs 3,676 crore.
Key points
- Divi's Laboratories said in an NSE filing that its Board approved results for the quarter ended 30 September 2026.
- Consolidated net profit was Rs 1,127 crore against Rs 689 crore a year earlier, a rise of 63.6%, the company's filing shows.
- Consolidated revenue from operations was Rs 3,676 crore, up 35.4% year on year and 19.4% from the previous quarter.
Divi's Laboratories said in a filing with the National Stock Exchange that its consolidated net profit for the quarter ended 30 September 2026 (Q2 FY27) rose 63.6% to Rs 1,127 crore from Rs 689 crore a year earlier. Consolidated revenue from operations rose 35.4% to Rs 3,676 crore. The Board approved the unaudited results at its meeting on 7 November 2026.
What Happened
According to the company's filing with the National Stock Exchange, the Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026. The figures below are consolidated and in rupees crore, as the filing gives them.
Revenue from operations was Rs 3,676 crore in the September 2026 quarter. That is 35.4% higher than Rs 2,715 crore in the same quarter a year earlier and 19.4% higher than Rs 3,080 crore in the previous quarter ended 30 June 2026. Total income, which includes other income, was Rs 3,770 crore, against Rs 2,860 crore a year earlier.
Profit before tax was Rs 1,505 crore, against Rs 912 crore in the year-earlier quarter. The company's press release, filed with the results, puts profit after tax at Rs 1,127 crore, against Rs 689 crore a year earlier. The press release does not give the previous quarter's profit, so no quarter-on-quarter comparison of profit is given here.
For the half year ended 30 September 2026, consolidated total income was Rs 6,907 crore, against Rs 5,389 crore a year earlier. Profit before tax was Rs 2,685 crore, against Rs 1,645 crore, and profit after tax was Rs 2,029 crore, against Rs 1,234 crore.
On a standalone basis, the filing shows revenue from operations of Rs 3,647 crore and profit for the period of Rs 1,140 crore in the September 2026 quarter. The company reported a foreign exchange gain of Rs 24 crore in the quarter on a consolidated basis, against Rs 63 crore a year earlier. The statutory auditors, Price Waterhouse Chartered Accountants LLP, carried out a limited review of the results.
What It Means
The filing is the company's own account of its performance in the quarter. It shows higher revenue and profit than in the same quarter of last year. The company makes active pharmaceutical ingredients, intermediates and nutraceutical ingredients, which it reports as a single business segment.
The results are unaudited and have been reviewed, not audited, by the statutory auditors. Shareholders and others can read the full filing on the National Stock Exchange website.
Oquilia Data: Divi's Laboratories Ltd. (NSE: DIVISLAB)
| Close, 6 Nov 2026 | Rs 10,320.50 (+1.78% on the day) |
|---|---|
| Return 1M / 3M / 6M / YTD / 1Y | +8.07% / +23.61% / +53.99% / +61.45% / +49.93% |
| Against Nifty 50, 1M / 3M / YTD | −1.83 / +22.01 / +65.65 points |
| 52-week closing high / low | Rs 10,320.50 (6 Nov 2026) / Rs 5,821.00 (6 Apr 2026) |
| Turnover, 20-session average | Rs 624.50 cr; 62.1% delivered; latest volume 1.3x |
| Insider trades, 90 days | 0 purchases (Rs 0.00 cr), 1 sale (Rs 16.83 cr) |
Closes adjusted for splits and bonuses; returns exclude dividends; insider figures from BSE filings. Facts from NSE's files, not investment advice.
Full record: Divi's Laboratories share price on Oquilia
Source: Company filing on NSE
Sources & Citations
- Company filing on NSE — National Stock Exchange of India